AiPD: Autoinhibited Protein Database

O15520

Gene name	FGF10
Protein name	Fibroblast growth factor 10
Names	FGF-10 , Keratinocyte growth factor 2
Species	Homo sapiens (Human)
KEGG Pathway	hsa:2255
EC number
Protein Class

Descriptions

The mammalian fibroblast growth factor (FGF)1 family contains at least 22 distinct polypeptides (FGF1–FGF22) that are expressed in a specific spatial and temporal pattern. FGF9 was originally described as a glia-activating factor and is expressed in the nervous system as a potent mitogen for glia cells. FGF9 adopts a beta-trefoil fold similar to other FGFs, but the N- and C-terminal regions outside the beta-trefoil core are ordered (typical FGFs have disordered tails) and involved in reversible dimerization. Due to the dimerization, a significant surface area is buried in the dimer interface that occludes a major receptor binding site of FGF9 within the beta-trefoil core. Sequence alignment of FGFs shows that most of the residues that participate in this interface in FGF9 are conserved in FGF16, suggesting that FGF16 may also dimerize for autoinhibition.

Autoinhibitory domains (AIDs)

69-76 (N-terminal helix) SS

Target domain	79-204 (beta-trefoil core)
Relief mechanism
Assay

AID

69-76 (N-terminal helix)

Target domain

79-204 (beta-trefoil core)

Relief mechanism

Assay

Accessory elements

No accessory elements

References

Plotnikov AN et al. (2001) "Crystal structure of fibroblast growth factor 9 reveals regions implicated in dimerization and autoinhibition", The Journal of biological chemistry, 276, 4322-9

Autoinhibited structure

Activated structure

2 structures for O15520

Entry ID	Method	Resolution	Chain	Position	Source
1NUN	X-ray	290 A	A	64-208	PDB
AF-O15520-F1	Predicted				AlphaFoldDB

267 variants for O15520

Variant ID(s)	Position	Change	Description	Diseaes Association	Provenance
rs1554040396 RCV000659640	1	M>V	Levy-Hollister syndrome [ClinVar]	Yes	ClinVar dbSNP
CA200465 RCV001152456 RCV000173344 RCV000888690 COSM145413 rs145373611	33	V>I	large_intestine haematopoietic_and_lymphoid_tissue Congenital absence of salivary gland [Cosmic, ClinVar]	Yes	ClinGen cosmic curated ClinVar 1000Genomes ESP ExAC TOPMed dbSNP gnomAD
RCV001196292 rs201790067	39	A>D	Levy-Hollister syndrome [ClinVar]	Yes	ClinVar ExAC dbSNP gnomAD
rs886060654 RCV000320633 CA10621917	62	S>R	Congenital absence of salivary gland [ClinVar]	Yes	TOPMed gnomAD ClinGen ClinVar dbSNP
rs1446723373 RCV001783273 RCV002471161	64	G>*	Levy-Hollister syndrome [ClinVar]	Yes	ClinVar dbSNP gnomAD
rs1554040364 RCV000659641	78	R>missing	Levy-Hollister syndrome [ClinVar]	Yes	ClinVar dbSNP
CA118872 RCV000007970 rs104893888 RCV000659642	80	R>S	Levy-Hollister syndrome Congenital absence of salivary gland [ClinVar]	Yes	ClinGen ClinVar TOPMed dbSNP
rs1554040361 RCV000659643	86	T>missing	Levy-Hollister syndrome [ClinVar]	Yes	ClinVar dbSNP
rs104893885 VAR_029888 CA118868 RCV003151710	106	C>F	Lacrimoauriculodentodigital syndrome 3 LADD3 [ClinVar, UniProt]	Yes	ClinGen ClinVar UniProt Ensembl dbSNP
RCV000659644 rs1554035763	119	G>missing	Levy-Hollister syndrome [ClinVar]	Yes	ClinVar dbSNP
RCV000659645 rs1554035757	134	M>K	Levy-Hollister syndrome [ClinVar]	Yes	ClinVar Ensembl dbSNP
RCV003151712 RCV000007968 rs104893887 CA118870	137	K>*	Lacrimoauriculodentodigital syndrome 3 Congenital absence of salivary gland [ClinVar]	Yes	ClinGen ClinVar Ensembl dbSNP
RCV000007971 CA118874 rs104893889	138	G>E	Congenital absence of salivary gland [ClinVar]	Yes	ClinGen ClinVar Ensembl dbSNP
rs104893886 VAR_029889 CA118869 RCV003151711	156	I>R	Lacrimoauriculodentodigital syndrome 3 LADD3 [ClinVar, UniProt]	Yes	ClinGen ClinVar UniProt Ensembl dbSNP
rs1332768200 RCV000659646 RCV003403519	181	N>H	FGF10-related condition Levy-Hollister syndrome [ClinVar]	Yes	ClinVar dbSNP gnomAD
rs1554035469 RCV000659647	184	G>R	Levy-Hollister syndrome [ClinVar]	Yes	ClinVar Ensembl dbSNP
CA118866 RCV000007964 rs104893884 RCV000760468	193	R>*	Congenital absence of salivary gland [ClinVar]	Yes	ClinGen ClinVar 1000Genomes ExAC TOPMed dbSNP gnomAD
rs150695565 COSM1207047 RCV002275300 RCV001157920	204	M>V	large_intestine Congenital absence of salivary gland [Cosmic, ClinVar]	Yes	cosmic curated ClinVar 1000Genomes ExAC TOPMed dbSNP gnomAD
RCV000335259 rs147715509 CA3258476 RCV000960252 RCV002502145 RCV000398550	207	H>P	Congenital absence of salivary gland [ClinVar]	Yes	ClinGen ClinVar 1000Genomes ESP ExAC TOPMed dbSNP gnomAD
rs1347979233	2	W>*		No	gnomAD
rs1347979233	2	W>C		No	gnomAD
rs199671312 COSM738690	2	W>S	lung Variant assessed as Somatic; MODERATE impact. [Cosmic, NCI-TCGA]	No	NCI-TCGA Cosmic cosmic curated Ensembl NCI-TCGA
RCV002026873 rs2111941241	4	W>R		No	ClinVar Ensembl dbSNP
rs1742169916	5	I>M		No	TOPMed
COSM3855396	5	I>R	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs1441196548	5	I>T		No	TOPMed gnomAD
TCGA novel rs747476439	6	L>M	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA ExAC TOPMed gnomAD
rs201659493	6	L>P		No	gnomAD
rs747476439	6	L>V		No	ExAC TOPMed gnomAD
rs2111941179	7	T>A		No	Ensembl
rs200886626	7	T>I		No	ExAC gnomAD
rs2111941151	8	H>Y		No	Ensembl
rs2111941131	9	C>F		No	Ensembl
rs1402567148	10	A>V		No	TOPMed gnomAD
rs2111941100 COSM94305	11	S>L	lung [Cosmic]	No	cosmic curated Ensembl
rs148032639	14	P>L		No	ESP ExAC TOPMed gnomAD
rs754826334	14	P>S		No	ExAC TOPMed gnomAD
rs754826334	14	P>T		No	ExAC TOPMed gnomAD
rs1579952227	15	H>P		No	Ensembl
rs1579952213	16	L>P		No	Ensembl
rs374755098	17	P>S		No	ESP ExAC TOPMed gnomAD
rs374755098	17	P>T		No	ESP ExAC TOPMed gnomAD
rs766989043	18	G>C		No	ExAC TOPMed gnomAD
rs766989043	18	G>S		No	ExAC TOPMed gnomAD
rs201408864	18	G>V		No	TOPMed gnomAD
rs761359401	19	C>G		No	ExAC TOPMed gnomAD
rs2111940924	19	C>Y		No	Ensembl
rs1742167894	20	C>S		No	TOPMed
rs1272336613	21	C>F		No	TOPMed gnomAD
rs1272336613	21	C>Y		No	TOPMed gnomAD
rs2111940849	22	C>F		No	Ensembl
rs200247528	22	C>R		No	1000Genomes ExAC TOPMed gnomAD
rs2111940840	22	C>W		No	Ensembl
rs2111940849	22	C>Y		No	Ensembl
rs2111940824	23	C>F		No	Ensembl
rs2111940824	23	C>Y		No	Ensembl
rs199806461	28	F>L	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	Ensembl NCI-TCGA
rs1742166990	29	L>F		No	TOPMed
rs1223515236	30	V>A		No	gnomAD
rs1284421241	30	V>L		No	TOPMed gnomAD
rs1284421241	30	V>M		No	TOPMed gnomAD
COSM1068457	31	S>F	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs762625065	31	S>T		No	ExAC gnomAD
rs2111940710	32	S>F		No	Ensembl
rs145373611	33	V>F		No	1000Genomes ESP ExAC TOPMed gnomAD
rs2111940638	34	P>H		No	Ensembl
rs2111940667	34	P>S		No	Ensembl
rs1007631855	35	V>A		No	TOPMed gnomAD
rs1579952118	36	T>P		No	Ensembl
rs1742166191	37	C>R		No	gnomAD
TCGA novel rs2111940565	37	C>Y	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Ensembl
rs1742166113	39	A>T		No	TOPMed
rs201790067	39	A>V		No	ExAC gnomAD
rs146669375	40	L>F		No	ESP ExAC TOPMed gnomAD
COSM1496129	40	L>I	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs146669375	40	L>V		No	ESP ExAC TOPMed gnomAD
rs772109862	41	G>D		No	ExAC TOPMed gnomAD
rs1429390732	42	Q>L		No	gnomAD
rs1409855200	43	D>G		No	TOPMed gnomAD
rs778802173	43	D>N		No	ExAC TOPMed gnomAD
rs778802173	43	D>Y		No	ExAC TOPMed gnomAD
rs201168313	44	M>L		No	1000Genomes ExAC TOPMed gnomAD
rs779848984	44	M>T		No	ExAC gnomAD
rs201168313	44	M>V		No	1000Genomes ExAC TOPMed gnomAD
rs1232465320	45	V>E		No	gnomAD
rs750371676	46	S>L		No	ExAC gnomAD
rs527933059	47	P>S		No	1000Genomes ExAC TOPMed gnomAD
rs751081612	49	A>D		No	ExAC TOPMed gnomAD
rs751081612	49	A>G		No	ExAC TOPMed gnomAD
COSM3855395 rs751081612	49	A>V	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic ExAC NCI-TCGA TOPMed gnomAD
rs144567587	50	T>S		No	ESP ExAC TOPMed gnomAD
COSM3776722 rs775259892	52	S>C	Variant assessed as Somatic; MODERATE impact. urinary_tract [NCI-TCGA, Cosmic]	No	NCI-TCGA Cosmic cosmic curated ExAC NCI-TCGA TOPMed gnomAD
rs775259892	52	S>F		No	ExAC TOPMed gnomAD
rs762714965	52	S>T		No	ExAC gnomAD
rs775259892	52	S>Y		No	ExAC TOPMed gnomAD
rs1742163718	53	S>F		No	Ensembl
TCGA novel	53	S>P	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA
rs1742163718	53	S>Y		No	Ensembl
rs2111940153 COSM1437688	54	S>F	large_intestine [Cosmic]	No	cosmic curated Ensembl
COSM3616762	55	S>F	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs2111940137	56	S>F		No	Ensembl
rs773650137	57	F>L		No	ExAC gnomAD
rs1742163480	57	F>S		No	Ensembl
rs761116992	57	F>V		No	ExAC gnomAD
rs1462552463	58	S>C		No	TOPMed gnomAD
rs1462552463	58	S>Y		No	TOPMed gnomAD
rs201038841	59	S>F		No	ExAC TOPMed gnomAD
TCGA novel	59	S>Y	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA
rs199850745	60	P>H		No	TOPMed
rs199850745	60	P>R		No	TOPMed
rs1742162872	60	P>S		No	TOPMed
rs774523215	61	S>C		No	ExAC TOPMed gnomAD
rs774523215	61	S>F		No	ExAC TOPMed gnomAD
rs898009871	62	S>G		No	TOPMed gnomAD
rs2111939874	63	A>S		No	Ensembl
TCGA novel	63	A>T	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA
rs201676495	64	G>E		No	ExAC TOPMed gnomAD
rs1446723373	64	G>R		No	gnomAD
rs201676495	64	G>V		No	ExAC TOPMed gnomAD
rs2111939812	65	R>M		No	Ensembl
rs1203071781	65	R>S		No	gnomAD
rs562084259	66	H>Y		No	1000Genomes
rs2111939767 RCV001874304	67	V>missing		No	ClinVar dbSNP
rs2111939735	68	R>G		No	Ensembl
rs1579951927 COSM1437687	68	R>Q	Variant assessed as Somatic; MODERATE impact. large_intestine [NCI-TCGA, Cosmic]	No	NCI-TCGA Cosmic cosmic curated TOPMed
rs2111939735	68	R>W		No	Ensembl
rs780222015	69	S>N		No	ExAC gnomAD
rs541818263	71	N>S		No	1000Genomes ExAC TOPMed gnomAD
rs745684641 COSM94304	72	H>Y	lung [Cosmic]	No	cosmic curated ExAC gnomAD
rs2111939617	75	G>*		No	Ensembl
rs1742161036	75	G>E		No	Ensembl
rs1742161036	75	G>V		No	Ensembl
rs199689272	76	D>E		No	1000Genomes ExAC
rs1436510729	78	R>H		No	Ensembl
rs1436510729	78	R>L		No	Ensembl
COSM3855394	79	W>G	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
COSM1437686	80	R>I	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs200056747	81	K>N		No	ExAC TOPMed gnomAD
TCGA novel	82	L>P	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA
rs1742160074	83	F>L		No	TOPMed
TCGA novel	84	S>F	Variant assessed as Somatic; HIGH impact. [NCI-TCGA]	No	NCI-TCGA
COSM449707	86	T>I	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs1742159760	88	Y>C		No	TOPMed
rs1554040360 CA658657444 RCV000523783	90	L>missing		No	ClinGen ClinVar dbSNP
COSM3429485	90	L>I	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs757950282	90	L>V		No	ExAC gnomAD
rs752464185	91	K>R		No	ExAC gnomAD
COSM6171277	93	E>D	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs1258016531	93	E>V		No	Ensembl
rs1363470725	95	N>K		No	gnomAD
rs1006967829	95	N>T		No	Ensembl
rs1274894561	97	K>E		No	TOPMed gnomAD
rs1742158663	97	K>N		No	TOPMed
rs2111939259 COSM4159881	98	V>I	thyroid [Cosmic]	No	cosmic curated Ensembl
COSM4159880 rs2111939248	99	S>G	thyroid [Cosmic]	No	cosmic curated Ensembl
rs764969764	99	S>N		No	ExAC gnomAD
rs759054084	99	S>R	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	ExAC NCI-TCGA gnomAD
rs2111939225	100	G>E		No	Ensembl
COSM4413111	100	G>R	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs1742158130	104	E>G		No	TOPMed
rs1742158208	104	E>Q		No	TOPMed
rs1428980854	105	N>S		No	TOPMed
rs200701392	107	P>L	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA TOPMed gnomAD
rs200701392	107	P>R		No	TOPMed gnomAD
rs1183240121	108	Y>H		No	gnomAD
rs961216513	109	S>N		No	gnomAD
rs1207676419	113	I>M		No	TOPMed gnomAD
rs1740187119	117	E>K		No	TOPMed gnomAD
rs1740187119	117	E>Q		No	TOPMed gnomAD
rs201385181	118	I>M		No	1000Genomes ExAC TOPMed gnomAD
rs1740186895	119	G>R		No	Ensembl
TCGA novel	120	V>A	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA
rs769710686	120	V>I		No	ExAC gnomAD
rs1225998924	122	A>T		No	gnomAD
rs2111688174	122	A>V		No	Ensembl
rs1467091511	123	V>A		No	TOPMed
rs776683911	123	V>I		No	ExAC TOPMed gnomAD
rs1740186270	124	K>R		No	Ensembl
rs1740186154	127	N>S		No	Ensembl
COSM1207048	128	S>N	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs1740186007	129	N>D		No	TOPMed gnomAD
rs145888320	130	Y>C		No	ESP ExAC TOPMed gnomAD
rs761123609	132	L>S		No	Ensembl
COSM3855392	132	L>V	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs2111687980	133	A>V		No	Ensembl
rs1740185736	135	N>D		No	TOPMed
rs746766662	135	N>S		No	ExAC gnomAD
rs1398855772	136	K>N		No	gnomAD
TCGA novel	137	K>M	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA
rs866583243	138	G>R	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	Ensembl NCI-TCGA
rs2111687801	139	K>*		No	Ensembl
rs200885171	142	G>A		No	Ensembl
rs200885171	142	G>D		No	Ensembl
rs1421578299	143	S>L		No	gnomAD
COSM5682558	144	K>*	Variant assessed as Somatic; HIGH impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs1740047632	147	N>S		No	TOPMed gnomAD
COSM3342865 rs2111667210	149	D>Y	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic Ensembl
TCGA novel	150	C>S	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA
rs2111667194	150	C>Y		No	Ensembl
rs1740047559 COSM1068455	151	K>T	Variant assessed as Somatic; MODERATE impact. oesophagus endometrium [NCI-TCGA, Cosmic]	No	NCI-TCGA Cosmic cosmic curated TOPMed
TCGA novel	155	R>G	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA
rs1409489572	155	R>K		No	gnomAD
rs1409489572	155	R>M		No	gnomAD
rs2111667052 COSM351231	157	E>D	lung Variant assessed as Somatic; MODERATE impact. [Cosmic, NCI-TCGA]	No	NCI-TCGA Cosmic cosmic curated Ensembl
rs2111667022	158	E>G		No	Ensembl
rs2111667037	158	E>K		No	Ensembl
TCGA novel	159	N>H	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA
rs2111666966	160	G>E		No	Ensembl
rs2111666945	161	Y>D		No	Ensembl
rs1206827871	163	T>I		No	gnomAD
rs2111666859	165	A>S		No	Ensembl
rs2111666844	165	A>V		No	Ensembl
rs1374899961	167	F>L		No	gnomAD
rs992179317	168	N>K		No	TOPMed gnomAD
rs2111666786	169	W>*		No	Ensembl
rs2111666773	169	W>*		No	Ensembl
rs758742613	170	Q>*		No	ExAC gnomAD
rs758742613	170	Q>K		No	ExAC gnomAD
rs1456457163	171	H>D		No	TOPMed
rs1456457163	171	H>N		No	TOPMed
rs1456457163	171	H>Y	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA TOPMed
rs1740046308	172	N>S		No	gnomAD
rs2111666663	173	G>A		No	Ensembl
rs1740046135	173	G>R		No	Ensembl
rs1740046135	173	G>W		No	Ensembl
rs1200591041	174	R>K		No	TOPMed
rs1740046017	174	R>S		No	TOPMed
rs1200591041	174	R>T		No	TOPMed
RCV000522239 rs1554035473 CA658657443	176	M>missing		No	ClinGen ClinVar dbSNP
TCGA novel	176	M>I	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA
rs1453394033	177	Y>F	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA gnomAD
rs1740045808	178	V>M		No	TOPMed
rs201342529	179	A>S		No	Ensembl
rs1332768200	181	N>D		No	gnomAD
rs571717817	183	K>R		No	Ensembl
rs2111666416	184	G>E		No	Ensembl
rs1740045309	185	A>T		No	gnomAD
rs1001460084	185	A>V		No	Ensembl
rs1442319696	187	R>K		No	TOPMed
rs183142365	188	R>I		No	1000Genomes
TCGA novel	188	R>K	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA
rs1013456350	190	Q>E		No	TOPMed gnomAD
rs1403015185	190	Q>H		No	gnomAD
rs866612964	190	Q>R		No	Ensembl
rs2111666194	192	T>I		No	Ensembl
rs2111666194	192	T>K		No	Ensembl
rs104893884	193	R>G		No	1000Genomes ExAC TOPMed gnomAD
rs1158466327	193	R>P		No	TOPMed gnomAD
COSM3828118 rs1158466327	193	R>Q	Variant assessed as Somatic; MODERATE impact. breast [NCI-TCGA, Cosmic]	No	NCI-TCGA Cosmic cosmic curated NCI-TCGA TOPMed gnomAD
rs1418284908	194	R>K		No	gnomAD
COSM738693	195	K>I	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs1165118219	195	K>R		No	TOPMed gnomAD
rs2111666078	196	N>D		No	Ensembl
rs2111666078	196	N>H		No	Ensembl
rs2111666078	196	N>Y		No	Ensembl
rs1163839847	197	T>I		No	gnomAD
rs2111666025	197	T>S		No	Ensembl
rs1235308786	198	S>C		No	TOPMed gnomAD
rs2111665914	199	A>T		No	Ensembl
COSM3855391	199	A>V	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs2111665883	200	H>D		No	Ensembl
rs2111665860	202	L>F		No	Ensembl
rs1740043544	205	V>A		No	gnomAD
rs773535125	205	V>M		No	ExAC TOPMed gnomAD
rs202151850	206	V>I		No	1000Genomes gnomAD
rs202151850 COSM1736678	206	V>L	central_nervous_system [Cosmic]	No	cosmic curated 1000Genomes gnomAD
rs147715509	207	H>R		No	1000Genomes ESP ExAC TOPMed gnomAD

2 associated diseases with O15520

[MIM: 180920]: Aplasia of lacrimal and salivary glands (ALSG)

A rare condition characterized by dry conjunctival mucosae, irritable eyes, epiphora (constant tearing), and xerostomia (dryness of the mouth), which increases risk of dental erosion, dental caries, periodontal disease, and oral infections. ALSG has variable expressivity, and affected individuals may have aplasia or hypoplasia of the lacrimal, parotid, submandibular, and sublingual glands and absence of the lacrimal puncta. . Note=The disease is caused by variants affecting the gene represented in this entry.

[MIM: 620193]: Lacrimo-auriculo-dento-digital syndrome 3 (LADD3)

A form of lacrimo-auriculo-dento-digital syndrome, an autosomal dominant disease characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed. . Note=The disease is caused by variants affecting the gene represented in this entry.

Without disease ID

A rare condition characterized by dry conjunctival mucosae, irritable eyes, epiphora (constant tearing), and xerostomia (dryness of the mouth), which increases risk of dental erosion, dental caries, periodontal disease, and oral infections. ALSG has variable expressivity, and affected individuals may have aplasia or hypoplasia of the lacrimal, parotid, submandibular, and sublingual glands and absence of the lacrimal puncta. . Note=The disease is caused by variants affecting the gene represented in this entry.
A form of lacrimo-auriculo-dento-digital syndrome, an autosomal dominant disease characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed. . Note=The disease is caused by variants affecting the gene represented in this entry.

No regional properties for O15520

Type	Name	Position	InterPro Accession
No domain, repeats, and functional sites for O15520

Functions

		Description
EC Number
Subcellular Localization	Secreted
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category	No pathway information available

6 GO annotations of cellular component

Name	Definition
cell surface	The external part of the cell wall and/or plasma membrane.
cytoplasm	The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.
extracellular region	The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite.
extracellular space	That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid.
nucleus	A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.
plasma membrane	The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins.

5 GO annotations of molecular function

Name	Definition
chemoattractant activity	Providing the environmental signal that initiates the directed movement of a motile cell or organism towards a higher concentration of that signal.
fibroblast growth factor receptor binding	Binding to a fibroblast growth factor receptor (FGFR).
growth factor activity	The function that stimulates a cell to grow or proliferate. Most growth factors have other actions besides the induction of cell growth or proliferation.
heparin binding	Binding to heparin, a member of a group of glycosaminoglycans found mainly as an intracellular component of mast cells and which consist predominantly of alternating alpha-(1->4)-linked D-galactose and N-acetyl-D-glucosamine-6-sulfate residues.
type 2 fibroblast growth factor receptor binding	Binding to a type 2 fibroblast growth factor receptor (FGFR2).

106 GO annotations of biological process

Name	Definition
actin cytoskeleton organization	A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising actin filaments and their associated proteins.
angiogenesis	Blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels.
animal organ morphogenesis	Morphogenesis of an animal organ. An organ is defined as a tissue or set of tissues that work together to perform a specific function or functions. Morphogenesis is the process in which anatomical structures are generated and organized. Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions.
blood vessel remodeling	The reorganization or renovation of existing blood vessels.
branch elongation involved in salivary gland morphogenesis	The differential growth of the salivary branches along their axis, resulting in the growth of a branch.
branching morphogenesis of an epithelial tube	The process in which the anatomical structures of branches in an epithelial tube are generated and organized. A tube is a long hollow cylinder.
bronchiole morphogenesis	The process in which a bronchiole is generated and organized. A bronchiole is the first airway branch that no longer contains cartilage; it is a branch of the bronchi.
bud elongation involved in lung branching	The process in which a bud in the lung grows out from the point where it is formed.
bud outgrowth involved in lung branching	The process in which a region of the lung epithelium initiates an outgrowth.
cell differentiation	The cellular developmental process in which a relatively unspecialized cell, e.g. embryonic or regenerative cell, acquires specialized structural and/or functional features that characterize a specific cell. Differentiation includes the processes involved in commitment of a cell to a specific fate and its subsequent development to the mature state.
determination of left/right symmetry	The establishment of an organism's body plan or part of an organism with respect to the left and right halves. The pattern can either be symmetric, such that the halves are mirror images, or asymmetric where the pattern deviates from this symmetry.
embryonic camera-type eye development	The process occurring during the embryonic phase whose specific outcome is the progression of the eye over time, from its formation to the mature structure.
embryonic digestive tract morphogenesis	The process in which the anatomical structures of the digestive tract are generated and organized during embryonic development. The digestive tract is the anatomical structure through which food passes and is processed.
embryonic genitalia morphogenesis	The process, occurring in the embryo, by which the anatomical structures of the genitalia are generated and organized.
embryonic pattern specification	The process that results in the patterns of cell differentiation that will arise in an embryo.
endothelial cell proliferation	The multiplication or reproduction of endothelial cells, resulting in the expansion of a cell population. Endothelial cells are thin flattened cells which line the inside surfaces of body cavities, blood vessels, and lymph vessels, making up the endothelium.
epithelial cell proliferation	The multiplication or reproduction of epithelial cells, resulting in the expansion of a cell population. Epithelial cells make up the epithelium, the covering of internal and external surfaces of the body, including the lining of vessels and other small cavities. It consists of cells joined by small amounts of cementing substances.
epithelial cell proliferation involved in salivary gland morphogenesis	The multiplication or reproduction of epithelial cells of the submandibular salivary gland, resulting in the expansion of a cell population and the shaping of the gland.
ERK1 and ERK2 cascade	An intracellular protein kinase cascade containing at least ERK1 or ERK2 (MAPKs), a MEK (a MAPKK) and a MAP3K. The cascade may involve 4 different kinases, as it can also contain an additional tier
establishment of mitotic spindle orientation	A cell cycle process that sets the alignment of mitotic spindle relative to other cellular structures.
extrinsic apoptotic signaling pathway in absence of ligand	The series of molecular signals in which a signal is conveyed from the cell surface to trigger the apoptotic death of a cell. The pathway starts with withdrawal of a ligand from a cell surface receptor, and ends when the execution phase of apoptosis is triggered.
female genitalia morphogenesis	The process in which the anatomical structures of female genitalia are generated and organized.
fibroblast growth factor receptor apoptotic signaling pathway	An apoptotic signaling pathway that starts with a ligand binding to, or being withdrawn from, a fibroblast growth factor receptor (FGFR).
fibroblast growth factor receptor signaling pathway	The series of molecular signals generated as a consequence of a fibroblast growth factor receptor binding to one of its physiological ligands.
fibroblast growth factor receptor signaling pathway involved in mammary gland specification	The series of molecular signals initiated by binding of a fibroblast growth factor to its receptor on the surface of al cell in the epidermis resulting in the formation of the mammary line. The mammary line is a ridge of epidermal cells that will form the mammary placodes.
fibroblast proliferation	The multiplication or reproduction of fibroblast cells, resulting in the expansion of the fibroblast population.
hair follicle morphogenesis	The process in which the anatomical structures of the hair follicle are generated and organized.
Harderian gland development	The process whose specific outcome is the progression of the Harderian gland over time, from its formation to the mature structure. The Harderian gland is an anterior orbital structure usually associated with the nictitating membrane, and produces and secretes a variety of substances to the eye, depending upon the species.
induction of positive chemotaxis	Any process that initiates the directed movement of a motile cell or organism towards a higher concentration in a concentration gradient of a specific chemical.
keratinocyte proliferation	The multiplication or reproduction of keratinocytes, resulting in the expansion of a cell population. Keratinocytes are epidermal cells which synthesize keratin and undergo a characteristic change as they move upward from the basal layers of the epidermis to the cornified (horny) layer of the skin.
lacrimal gland development	The process whose specific outcome is the progression of the lacrimal gland over time, from its formation to the mature structure. The lacrimal gland produces secretions that lubricate and protect the cornea of the eye.
limb bud formation	The process pertaining to the initial formation of a limb bud from unspecified parts. This process begins with the formation of a local condensation of mesenchyme cells within the prospective limb field, and ends when a limb bud is recognizable.
limb development	The process whose specific outcome is the progression of a limb over time, from its formation to the mature structure. A limb is an appendage of an animal used for locomotion or grasping. Examples include legs, arms or some types of fin.
lung epithelium development	The biological process whose specific outcome is the progression of the lung epithelium from an initial condition to its mature state. This process begins with the formation of lung epithelium and ends with the mature structure. The lung epithelium is the specialized epithelium that lines the inside of the lung.
lung proximal/distal axis specification	The establishment, maintenance and elaboration of the proximal/distal axis of the lung. The proximal/distal axis of the lung is defined by a line that runs from the trachea to the alveoli.
lung saccule development	The biological process whose specific outcome is the progression of a lung saccule from an initial condition to its mature state. The lung saccule is the primitive gas exchange portion of the lung composed of type I and type II cells.
male genitalia morphogenesis	The process in which the anatomical structures of male genitalia are generated and organized.
mammary gland bud formation	The morphogenetic process in which a bud forms from the mammary placode. A mammary bud is bulb of epithelial cells that is distinct from the surrounding epidermis.
mesenchymal cell differentiation involved in lung development	The process in which a relatively unspecialized cell acquires specialized features of a mesenchymal cell of the lung. A mesenchymal cell is a loosely associated cell that is part of the connective tissue in an organism. Mesenchymal cells give rise to more mature connective tissue cell types.
mesenchymal-epithelial cell signaling involved in lung development	Any process that mediates the transfer of information from a mesenchymal cell to an epithelial cell and contributes to the development of the lung.
mesonephros development	The process whose specific outcome is the progression of the mesonephros over time, from its formation to the mature structure. In mammals, the mesonephros is the second of the three embryonic kidneys to be established and exists only transiently. In lower vertebrates such as fish and amphibia, the mesonephros will form the mature kidney.
metanephros development	The process whose specific outcome is the progression of the metanephros over time, from its formation to the mature structure. In mammals, the metanephros is the excretory organ of the fetus, which develops into the mature kidney and is formed from the rear portion of the nephrogenic cord. The metanephros is an endocrine and metabolic organ that filters the blood and excretes the end products of body metabolism in the form of urine.
metanephros morphogenesis	The process in which the anatomical structures of the metanephros are generated and organized.
muscle cell fate commitment	The process in which the cellular identity of muscle cells is acquired and determined.
negative regulation of epithelial cell differentiation	Any process that stops, prevents, or reduces the frequency, rate or extent of epithelial cell differentiation.
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	Any process that stops, prevents or reduces the frequency, rate or extent of extrinsic apoptotic signaling pathway in absence of ligand.
negative regulation of stem cell proliferation	Any process that stops, prevents or reduces the frequency, rate or extent of stem cell proliferation.
odontogenesis of dentin-containing tooth	The process whose specific outcome is the progression of a dentin-containing tooth over time, from its formation to the mature structure. A dentin-containing tooth is a hard, bony organ borne on the jaw or other bone of a vertebrate, and is composed mainly of dentin, a dense calcified substance, covered by a layer of enamel.
organ induction	The interaction of two or more cells or tissues that causes them to change their fates and specify the development of an organ.
otic vesicle formation	The process resulting in the transition of the otic placode into the otic vesicle, a transient embryonic structure formed during development of the vertebrate inner ear.
pancreas development	The process whose specific outcome is the progression of the pancreas over time, from its formation to the mature structure. The pancreas is an endoderm derived structure that produces precursors of digestive enzymes and blood glucose regulating hormones.
pituitary gland development	The progression of the pituitary gland over time from its initial formation until its mature state. The pituitary gland is an endocrine gland that secretes hormones that regulate many other glands.
positive chemotaxis	The directed movement of a motile cell or organism towards a higher concentration of a chemical.
positive regulation of ATP-dependent activity	Any process that activates or increases the rate of an ATP-dependent activity.
positive regulation of canonical Wnt signaling pathway	Any process that increases the rate, frequency, or extent of the Wnt signaling pathway through beta-catenin, the series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell, followed by propagation of the signal via beta-catenin, and ending with a change in transcription of target genes.
positive regulation of DNA repair	Any process that activates or increases the frequency, rate or extent of DNA repair.
positive regulation of endothelial cell proliferation	Any process that activates or increases the rate or extent of endothelial cell proliferation.
positive regulation of epithelial cell migration	Any process that activates or increases the frequency, rate or extent of epithelial cell migration.
positive regulation of epithelial cell proliferation	Any process that activates or increases the rate or extent of epithelial cell proliferation.
positive regulation of epithelial cell proliferation involved in wound healing	Any process that activates or increases the rate or extent of epithelial cell proliferation, contributing to the restoration of integrity to a damaged tissue following an injury.
positive regulation of ERK1 and ERK2 cascade	Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade.
positive regulation of fibroblast proliferation	Any process that activates or increases the frequency, rate or extent of multiplication or reproduction of fibroblast cells.
positive regulation of G1/S transition of mitotic cell cycle	Any signalling pathway that increases or activates a cell cycle cyclin-dependent protein kinase to modulate the switch from G1 phase to S phase of the mitotic cell cycle.
positive regulation of gene expression	Any process that increases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA).
positive regulation of hair follicle cell proliferation	Any process that activates or increases the rate or extent of hair follicle cell proliferation.
positive regulation of keratinocyte migration	Any process that activates or increases the frequency, rate or extent of keratinocyte migration.
positive regulation of keratinocyte proliferation	Any process that increases the rate, frequency or extent of keratinocyte proliferation. Keratinocyte proliferation is the multiplication or reproduction of keratinocytes, resulting in the expansion of a cell population.
positive regulation of lymphocyte proliferation	Any process that activates or increases the rate or extent of lymphocyte proliferation.
positive regulation of MAPK cascade	Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the MAPK cascade.
positive regulation of Notch signaling pathway	Any process that activates or increases the frequency, rate or extent of the Notch signaling pathway.
positive regulation of peptidyl-tyrosine phosphorylation	Any process that activates or increases the frequency, rate or extent of the phosphorylation of peptidyl-tyrosine.
positive regulation of protein phosphorylation	Any process that activates or increases the frequency, rate or extent of addition of phosphate groups to amino acids within a protein.
positive regulation of Ras protein signal transduction	Any process that activates or increases the frequency, rate or extent of Ras protein signal transduction.
positive regulation of stem cell proliferation	Any process that activates or increases the frequency, rate or extent of stem cell proliferation.
positive regulation of transcription by RNA polymerase II	Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter.
positive regulation of urothelial cell proliferation	Any process that activates or increases the rate or extent of urothelial cell proliferation.
positive regulation of vascular endothelial growth factor receptor signaling pathway	Any process that activates or increases the frequency, rate or extent of vascular endothelial growth factor receptor signaling pathway activity.
positive regulation of white fat cell proliferation	Any process that activates or increases the rate or extent of white fat cell proliferation.
prostatic bud formation	The morphogenetic process in which a region of the fetal urogenital sinus epithelium is specified to become the prostate, resulting in prostate bud outgrowth.
protein localization to cell surface	A process in which a protein is transported to, or maintained in, a location within the external part of the cell wall and/or plasma membrane.
radial glial cell differentiation	The process in which neuroepithelial cells of the neural tube give rise to radial glial cells, specialized bipotential progenitors cells of the brain. Differentiation includes the processes involved in commitment of a cell to a specific fate.
regulation of activin receptor signaling pathway	Any process that modulates the frequency, rate or extent of the activity of any activin receptor signaling pathway.
regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling	Any process that modulates the rate, frequency, or extent of branching involved in salivary gland morphogenesis as a result of signals being generated by the mesenchyme and received and interpreted by the salivary gland epithelium.
regulation of saliva secretion	Any process that modulates the frequency, rate or extent of the regulated release of saliva from a cell or a tissue.
regulation of smoothened signaling pathway	Any process that modulates the frequency, rate or extent of smoothened signaling.
response to estradiol	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of stimulus by estradiol, a C18 steroid hormone hydroxylated at C3 and C17 that acts as a potent estrogen.
response to lipopolysaccharide	Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipopolysaccharide stimulus; lipopolysaccharide is a major component of the cell wall of gram-negative bacteria.
salivary gland development	The process whose specific outcome is the progression of the salivary gland over time, from its formation to the mature structure. Salivary glands include any of the saliva-secreting exocrine glands of the oral cavity.
secretion by lung epithelial cell involved in lung growth	The controlled release of liquid by a lung epithelial cell that contributes to an increase in size of the lung as part of its development.
semicircular canal fusion	Creation of the central hole of the semicircular canal by sealing the edges of the pouch that forms during the process of semicircular canal formation.
smooth muscle cell differentiation	The process in which a relatively unspecialized cell acquires specialized features of a smooth muscle cell; smooth muscle lacks transverse striations in its constituent fibers and are almost always involuntary.
somatic stem cell population maintenance	Any process by which an organism retains a population of somatic stem cells, undifferentiated cells in the embryo or adult which can undergo unlimited division and give rise to cell types of the body other than those of the germ-line.
spleen development	The process whose specific outcome is the progression of the spleen over time, from its formation to the mature structure. The spleen is a large vascular lymphatic organ composed of white and red pulp, involved both in hemopoietic and immune system functions.
stem cell proliferation	The multiplication or reproduction of stem cells, resulting in the expansion of a stem cell population. A stem cell is a cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into specialized cells.
submandibular salivary gland formation	The developmental process pertaining to the initial formation of a submandibular salivary gland. This process begins with a thickening of the epithelium next to the tongue and ends when a bud linked to the oral surface is formed.
tear secretion	The regulated release of the aqueous layer of the tear film from the lacrimal glands. Tears are the liquid product of a process of lacrimation to clean and lubricate the eyes. Tear fluid contains water, mucin, lipids, lysozyme, lactoferrin, lipocalin, lacritin, immunoglobulins, glucose, urea, sodium, and potassium.
thymus development	The process whose specific outcome is the progression of the thymus over time, from its formation to the mature structure. The thymus is a symmetric bi-lobed organ involved primarily in the differentiation of immature to mature T cells, with unique vascular, nervous, epithelial, and lymphoid cell components.
thyroid gland development	The process whose specific outcome is the progression of the thyroid gland over time, from its formation to the mature structure. The thyroid gland is an endoderm-derived gland that produces thyroid hormone.
tissue regeneration	The regrowth of lost or destroyed tissues.
type II pneumocyte differentiation	The process in which a relatively unspecialized cell acquires specialized features of a type II pneumocyte. A type II pneumocyte is a surfactant secreting cell that contains abundant cytoplasm containing numerous lipid-rich multilamellar bodies.
urothelial cell proliferation	The multiplication or reproduction of urothelial cells, resulting in the expansion of a cell population. Urothelial cells make up a layer of transitional epithelium in the wall of the bladder, ureter, and renal pelvis, external to the lamina propria.
vascular endothelial growth factor receptor signaling pathway	The series of molecular signals initiated by a ligand binding to a vascular endothelial growth factor receptor (VEGFR) on the surface of the target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.
white fat cell differentiation	The process in which a relatively unspecialized cell acquires specialized features of a white adipocyte, an animal connective tissue cell involved in energy storage. White adipocytes have cytoplasmic lipids arranged in a unique vacuole.
white fat cell proliferation	The multiplication or reproduction of white fat cells by cell division, resulting in the expansion of their population.
Wnt signaling pathway	The series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell and ending with a change in cell state.
wound healing	The series of events that restore integrity to a damaged tissue, following an injury.

28 homologous proteins in AiPD

UniProt AC	Gene Name	Protein Name	Species	Evidence Code
P48801	FGF3	Fibroblast growth factor 3	Gallus gallus (Chicken)	SS
O43320	FGF16	Fibroblast growth factor 16	Homo sapiens (Human)	EV SS
P10767	FGF6	Fibroblast growth factor 6	Homo sapiens (Human)	SS
P11487	FGF3	Fibroblast growth factor 3	Homo sapiens (Human)	SS
P31371	FGF9	Fibroblast growth factor 9	Homo sapiens (Human)	EV
Q92914	FGF11	Fibroblast growth factor 11	Homo sapiens (Human)	SS
Q9HCT0	FGF22	Fibroblast growth factor 22	Homo sapiens (Human)	SS
Q9NP95	FGF20	Fibroblast growth factor 20	Homo sapiens (Human)	SS
Q9NSA1	FGF21	Fibroblast growth factor 21	Homo sapiens (Human)	PR
P08620	FGF4	Fibroblast growth factor 4	Homo sapiens (Human)	PR
P21658	Fgf6	Fibroblast growth factor 6	Mus musculus (Mouse)	SS
Q9ESS2	Fgf22	Fibroblast growth factor 22	Mus musculus (Mouse)	SS
P54130	Fgf9	Fibroblast growth factor 9	Mus musculus (Mouse)	SS
Q9JJN1	Fgf21	Fibroblast growth factor 21	Mus musculus (Mouse)	PR
Q9ESL8	Fgf16	Fibroblast growth factor 16	Mus musculus (Mouse)	SS
Q9ESL9	Fgf20	Fibroblast growth factor 20	Mus musculus (Mouse)	SS
P11403	Fgf4	Fibroblast growth factor 4	Mus musculus (Mouse)	PR
P61329	Fgf12	Fibroblast growth factor 12	Mus musculus (Mouse)	PR
P05524	Fgf3	Fibroblast growth factor 3	Mus musculus (Mouse)	SS
O35565	Fgf10	Fibroblast growth factor 10	Mus musculus (Mouse)	SS
Q95L12	FGF9	Fibroblast growth factor 9	Sus scrofa (Pig)	SS
Q9EST9	Fgf20	Fibroblast growth factor 20	Rattus norvegicus (Rat)	SS
O54769	Fgf16	Fibroblast growth factor 16	Rattus norvegicus (Rat)	SS
P36364	Fgf9	Fibroblast growth factor 9	Rattus norvegicus (Rat)	SS
P70492	Fgf10	Fibroblast growth factor 10	Rattus norvegicus (Rat)	SS
Q6PBT8	fgf1	Putative fibroblast growth factor 1	Danio rerio (Zebrafish) (Brachydanio rerio)	SS
Q2HXK8	fgf16	Fibroblast growth factor 16	Danio rerio (Zebrafish) (Brachydanio rerio)	SS
P48802	fgf3	Fibroblast growth factor 3	Danio rerio (Zebrafish) (Brachydanio rerio)	SS

10	20	30	40	50	60
MWKWILTHCA	SAFPHLPGCC	CCCFLLLFLV	SSVPVTCQAL	GQDMVSPEAT	NSSSSSFSSP
70	80	90	100	110	120
SSAGRHVRSY	NHLQGDVRWR	KLFSFTKYFL	KIEKNGKVSG	TKKENCPYSI	LEITSVEIGV
130	140	150	160	170	180
VAVKAINSNY	YLAMNKKGKL	YGSKEFNNDC	KLKERIEENG	YNTYASFNWQ	HNGRQMYVAL
190	200
NGKGAPRRGQ	KTRRKNTSAH	FLPMVVHS